LigaSure Large‑Vessel Sealer: From Technological Innovation to Surgical Revolution – A Benchmark in Energy‑Based Surgery
I. Introduction: A Paradigm Shift in Surgical Hemostasis
Safe and efficient hemostasis has always been one of the core challenges in the evolution of surgical procedures. Traditional vascular ligation relies on sutures, metal clips, or ultrasonic shears, but when dealing with large vessels or thick tissue bundles, these methods are often time‑consuming and carry risks of bleeding or foreign‑body retention. The LigaSure™ Vessel Sealing System (also known as the Ligasure vascular closure system) fundamentally changed this landscape. Since its market introduction in 1998, LigaSure technology has been used in more than 35 million procedures across over 65 countries, establishing itself as the gold standard for large‑vessel sealing.
II. Development History: Over Two Decades of Continuous Innovation
The evolution of LigaSure itself reflects the broader history of energy‑based instruments in minimally invasive surgery:
· 1999: The world’s first energy‑based ligation system – the LigaSure™ 8 device – was launched.
· 2004: The first 5‑mm laparoscopic instrument with an integrated blade – LigaSure™ V (dolphin‑nose jaw) – was introduced.
· 2008: Blunt‑tip instruments were released.
· 2014: The first generation of LigaSure™ Maryland jaw instruments became available.
· 2018: New‑generation blunt and Maryland jaw instruments incorporated nano‑coating technology.
· 2023: The LigaSure™ XP Maryland jaw instrument was launched, integrating the best features of all previous devices.
· 2025: The robotic version, LigaSure RAS, received CE approval and can be used with the Hugo™ robotic surgical system.
III. Core Technology: The Perfect Synergy of Intelligence and Pressure
At its core, LigaSure is an intelligent bipolar electrothermal vessel sealing device (EBVS). Its key technology can be summarised as a triple synergy of “real‑time feedback + intelligent generator + precise pressure”:
1. Intelligent Impedance Feedback: Through built‑in TissueFect™ tissue‑sensing technology, the system monitors tissue impedance up to 434,000 times per second, automatically identifying changes in tissue composition between the jaws and instantaneously adjusting the output voltage and current. When the tissue reaches the optimal sealing state, the system automatically stops energy delivery and emits an audible signal.
2. Precise Energy Control: Unlike conventional bipolar electrosurgery, LigaSure operates at a lower voltage but with a larger contact area, allowing higher current flow. It precisely controls tissue temperature within the 70–100°C fusion window, ensuring adequate collagen denaturation and fusion while preventing carbonisation.
3. Mechanical Pressure Synergy: The jaws deliver a pressure of up to 5,000–7,000 kPa, causing collagen and fibrin in the vessel wall to dissolve, denature, and fuse, forming a permanent transparent seal zone of 2–3 mm. This seal can withstand pressures three times normal human systolic blood pressure.
This combination enables LigaSure to safely and permanently seal arteries and veins up to 7 mm in diameter, as well as lymphatic vessels and tissue bundles.
IV. Clinical Advantages and Applications
Compared with conventional suture ligation, metal clips, or ultrasonic shears, LigaSure offers significant clinical benefits:
· Reduced intraoperative bleeding: Significantly lowers blood loss in colorectal, gynaecological, and urological procedures.
· Shorter operative time: The average sealing cycle takes only 2 to 4 seconds, greatly improving surgical efficiency.
· Minimal thermal spread: The lateral thermal effect is only 1.5–2 mm, effectively protecting adjacent vital structures.
· No foreign‑body retention: No sutures or clips are left behind, eliminating foreign‑body reactions.
· Shorter hospital stay: Multiple studies have shown a reduction in postoperative hospitalisation days.
In terms of indications, LigaSure is widely used in general surgery (gastrectomy, colectomy, splenectomy, thyroidectomy, etc.), gynaecology (hysterectomy, salpingo‑oophorectomy, etc.), urology (nephrectomy, cystectomy, radical prostatectomy, etc.), thoracic surgery (pulmonary vessel management), and hepatobiliary surgery, among other specialties.
V. Operational Tips and Safety Principles
Correct usage is critical to ensuring safety and efficacy:
· Adequate exposure: The target vessel should be clearly visible, appropriately skeletonised, and placed centrally between the jaws.
· Perpendicular clamping: The jaws should be oriented perpendicular to the vessel, ensuring the tissue is fully captured.
· Wait for confirmation: Continuously press the activation button until the audible/visual signal indicates completion of sealing.
· Avoid overloading: Do not attempt to seal excessively thick tissue bundles in one go; divide them into smaller bundles.
· Activate under direct vision: Always activate the device under direct visual control to avoid injury to adjacent structures such as the ureter, bile duct, or bowel.
VI. Latest Advances: The Era of Robotic Surgery
In July 2025, Medtronic announced that LigaSure RAS had received CE approval – the first LigaSure instrument specifically designed for robotic‑assisted surgery, compatible with the Hugo™ RAS system. LigaSure RAS can seal vessels consistently in approximately 2 seconds while minimising thermal spread to surrounding tissues. This milestone marks the official entry of this mature technology into the new era of robotic surgery.
VII. Conclusion
Since its debut in 1998, the LigaSure large‑vessel sealer has undergone more than two decades of continuous innovation and clinical validation. By ingeniously combining intelligent feedback, precise energy delivery, and mechanical pressure, it provides surgeons with a reliable, efficient, and safe solution for managing large vessels. With the introduction of the robotic version, LigaSure technology continues to lead the direction of energy‑based surgery, bringing safer and more minimally invasive surgical experiences to more patients worldwide.
